RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer-Reference-Cited by-同舟云学术

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

Published:2019-06-24 Issue:3 Volume:121 Page:211-217
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Morgensztern Daniel,Rose Michal,Waqar Saiama N.,Morris John,Ma Patrick C.,Reid Thomas,Brzezniak Christina E.,Zeman Karen G.,Padmanabhan Arvinda,Hirth JoAnn,I. Spira Alexander,Trepel Jane B,Padda Sukhmani K.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0504-8.pdf

Reference31 articles.

1. Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A. et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 24, 4539–4544 (2006).

2. Pietanza, M. C., Byers, L. A., Minna, J. D. & Rudin, C. M. Small cell lung cancer: will recent progress lead to improved outcomes? Clin. Cancer Res. 21, 2244–2255 (2015).

3. Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J. et al. Small cell lung cancer. J. Natl Compr. Canc. Netw. 11, 78–98 (2013).

4. Postmus, P. E., Berendsen, H. H., van Zandwijk, N., Splinter, T. A., Burghouts, J. T. & Bakker, W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur. J. Cancer Clin. Oncol. 23, 1409–1411 (1987).

5. Giaccone, G., Ferrati, P., Donadio, M., Testore, F. & Calciati, A. Reinduction chemotherapy in small cell lung cancer. Eur. J. Cancer Clin. Oncol. 23, 1697–1699 (1987).

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lost at SCLC: a review of potential platinum sensitizers;Cancer and Metastasis Reviews;2024-08-23

2. The Cancer Antioxidant Regulation System in Therapeutic Resistance;Antioxidants;2024-06-27

3. The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics;Genes;2024-05-27

4. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities;Signal Transduction and Targeted Therapy;2024-05-22

5. An “All‐In‐One” Immunomodulator‐Engineered Clinical Translatable Immunotherapy of Advanced Hepatocellular Carcinoma;Advanced Healthcare Materials;2024-04-03